KDM6A mutation and expression in gastric cancer are associated with prognosis
10.3760/cma.j.cn112152-20190528-00334
- VernacularTitle:KDM6A突变及表达对胃癌预后的影响
- Author:
Longlong LI
1
;
Zhiguo HUANG
;
Yiwen WANG
;
Ming LU
;
Kongwang HU
Author Information
1. 安徽医科大学第一附属医院胃肠外科，合肥 230022
- Keywords:
Stomach neoplasms;
KDM6A;
Prognosis
- From:
Chinese Journal of Oncology
2020;42(8):648-652
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between KDM6A mutation or expression and clinicopathological characteristics of gastric cancer.Methods:Fifty-seven cases of gastric cancer tissues were analyzed by second-generation sequencing, and bioinformation database such as Cbioportal, Kaplan Meier-Plotter, and the Human Protein Atlas were used to analyze the relationship between KDM6A mutation and clinicopathological characteristics of gastric cancer.Results:Among 57 gastric cancer samples, 14 were KDM6A mutation, and the mutation proportion was 24.6%. Compared with the non-mutation group, the Borrmann classification, T stage, TNM stage and tumor diameter of KDM6A mutant group were significantly different (all P<0.05). The median survival time of the KDM6A mutant patients was 53.5 months, significantly shorter than 72.0 months of the KDM6A non-mutation patients ( P=0.007). The analysis result of Kaplan Meier-Plotter database showed that, among all of the 875 patients, 655 patients had low KDM6A expression and 220 patients had high expression. The median survival time of patients with low expression was 23.5 months, significantly shorter than 30.8 months of patients with high expression ( P=0.002). In male, gastric cancer patients with stage Ⅲ, intestinal type, diffuse type, simple surgical treatment and fluorouracil chemotherapy, the expression of KDM6A is related to the patient's overall survival time (all P<0.05). The analysis result of Cbioportal database showed that, among all of the 1 172 gastric cancer patients, 70 patients with KDM6A mutation, 1100 patients with non-mutation. The median overall survival time of mutant patients was 28.9 months, significantly shorter than 35.9 months of non-mutation patients ( P<0.001). The analysis result of Human Protein Atlas database showed that, among all of the 355 gastric cancer patients, 97 patients had high KDM6A expression and 258 patients had low KDM6A expression. The median survival time of patients with low expression was 13.7 months, significantly shorter than 19.8 months of patients with high expression ( P=0.022). Conclusions:The survival time of gastric cancer patients with KDM6A mutation or low expression is shorter. The mutation and expression of KDM6A are related to clinical pathological factors, which may become a potential target for the diagnosis and treatment of gastric cancer.
